The Psychiatry & Behavioral Health Learning Network published online a transcript of a talk given by Dr. Nora Volkow, director of the National Institute on Drug Abuse (NIDA), at the Rx Drug Abuse & Heroin Summit held in Atlanta in April 2022. In the interview, she discusses recent updates on the opioid epidemic and highlights how NIDA is working to shift its focus to actively address the changing landscape of the epidemic.
One part of her message was the importance of prevention, stating, "if we do not address the issue of preventing drug use very early, adolescents who are the ones that are starting to experiment, we will always be catching up, new drug for the other."
The US FDA has not approved any medications for the treatment of methamphetamine (METH) use disorders. Currently, cognitive-behavioral and contingency-management interventions are the most effective treatments. IXT-m200, a monoclonal antibody that specifically binds METH in the blood, is being developed as a pharmacological treatment for use in conjunction with behavior therapies. Based on nonclinical studies, IXT-m200 is expected to alter METH pharmacokinetics in human subjects resulting in reduced or blocked METH subjective effects that reinforce METH use.
Methadone and various formulations containing buprenorphine are treatment drugs used in medication-assisted treatment, usually referred to as MAT. These are the MAT drugs approved for treatment of opioid addiction (opioid painkillers, heroin, fentanyl). We will take a look at the minus side as well as the plus side of these opioid addition treatment drugs. Treatment with MAT drugs can be right for some people. But anyone choosing this treatment so they can leave addiction behind should be prepared for the minus side of MAT.
In 2018, McKesson committed the astronomical sum of $100 million to support a new non-profit group, the FORE Foundation. Is there any reason, really, to think twice about this collaboration between McKesson and the FORE Foundation? The answer might be "yes." This type of action was one of the tactics used by Purdue Pharma to smooth the path to increased opioid prescribing—getting a non-profit to spend your money making increased use of your products possible. In the end, even this move could be all about profits.
The powerful hallucinogen LSD (lysergic acid diethylamide) has potential as a treatment for alcoholism, according to a retrospective analysis of studies published in the late 1960s and early 1970s…
Psychedelics were promoted by psychiatrists in the 1950s as having a range of medical uses — to treat conditions such as schizophrenia, for example — before political pressures in the United States and elsewhere largely ended the work.
While pharmaceutical companies like Purdue Pharma, Johnson & Johnson and Teva Pharmaceuticals have been settling one lawsuit after another for sums reaching billions of dollars, they have also been establishing themselves as vendors of addiction treatment drugs or overdose antidote drugs. In some cases, they also continue to market and sell addictive drugs through a wholly-owned subsidiary, while the parent company apparently swears off trafficking in these drugs as part of their settlement agreements. We take a closer look at some of these companies and the front-end and back-end gravy trains they've built for themselves.
SUBSCRIBE DONATE NOW Search Posts and/or Pages DONATE NOW Date: | Contributor: Source: ( ) | Category: Summary and Analysis... This article identifies what appears to be a new form of buprenorphine as a "new drug" to address opioid addictions. According to the article, Buvidal is a slow-release version of buprenorphine that can be injected either once a week or once a month.
One photo shows a long line of people standing close together while waiting for methadone at the counter of an opioid treatment program in Minneapolis last Friday. Another shows a crowded waiting room last Saturday at a similar clinic in Winston-Salem, N.C.
These images, collected by an advocacy group, show that many people are having to risk Covid-19 infection to get their addiction-treatment medication — weeks after the federal government relaxed rules that require people to show up at clinics every day to get methadone.
Aimed at reducing the spread of the novel coronavirus, the new rules allow people considered “stable” to take home up to a 28-day supply of methadone under a blanket exception, and people considered “less than stable” to take home up to a 14-day supply. But advocates for people recovering from addiction say compliance with the new guidelines has been inconsistent.